Pharmacological inhibition of SMYD2 protects against cisplatin-induced acute kidney injury in mice
The histone methyltransferase SET and MYND domain protein 2 (SMYD2) has been implicated in tumorigenesis through methylating histone H3 at lysine36 (H3K36) and some non-histone substrates. Currently, the role of SMYD2 in acute kidney injury (AKI) remains unknown. Here, we investigated the effects of...
Main Authors: | Binbin Cui, Xiying Hou, Mengjun Liu, Qing Li, Chao Yu, Shenglei Zhang, Yi Wang, Jun Wang, Shougang Zhuang, Feng Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-08-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.829630/full |
Similar Items
-
Targeting Epigenetic Changes Mediated by Members of the SMYD Family of Lysine Methyltransferases
by: Alyssa Padilla, et al.
Published: (2023-02-01) -
Identifying novel SMYD3 interactors on the trail of cancer hallmarks
by: Candida Fasano, et al.
Published: (2022-01-01) -
Effect of SMYD3 on Biological Behavior and H3K4 Methylation in Bladder Cancer [Retraction]
by: Wu X, et al.
Published: (2023-07-01) -
Macrophages in Renal Injury, Repair, Fibrosis Following Acute Kidney Injury and Targeted Therapy
by: Hui Chen, et al.
Published: (2022-07-01) -
Overexpression of SMYD3 Promotes Autosomal Dominant Polycystic Kidney Disease by Mediating Cell Proliferation and Genome Instability
by: Ewud Agborbesong, et al.
Published: (2024-03-01)